Trial Profile
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EINSTEIN-CHOICE
- Sponsors Bayer
- 07 Sep 2018 Results published in the Chest
- 12 Dec 2017 Results assessing Healthcare Cost impact of Rivaroxaban Versus Aspirin, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 30 Oct 2017 According to a Janssen media release, based on the data from this trial the U.S. FDA approved the 10 mg once-daily dose of XARELTO (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy under a FDA Priority Review.